Comprehensive Notes on Musculoskeletal Studies in Nuclear Medicine

Musculoskeletal Studies in Nuclear Medicine — Comprehensive Notes

Bone composition and hydroxyapatite

• Bone is a very active living tissue composed of organic and inorganic components.
  • Organic matrix: mainly collagen fibers (≈90% of all organic material).
  • Organic material accounts for about 30% of bone mass.
  • Inorganic portion: salts (majority as hydroxyapatite) ≈45% of bone mass.
  • Water content ≈25% of bone mass.
• Hydroxyapatite (major inorganic salt) is present as small crystals. They are often represented or discussed as:
  • Hydroxyapatite formula (as given in the transcript): $3Ca<em>3(PO</em>4)<em>2Ca(OH)</em>2$
  • Note: Hydroxyapatite is commonly written as $ext{Ca}<em>{10}( ext{PO}</em>4)<em>6( ext{OH})</em>2$ in standard chemistry, but the transcript presents the alternative form.
• Role of hydroxyapatite: provides a large surface area for ion exchange and interacts with various ions in the extracellular fluid due to extensive vascularization of bone.

Bone cell types and functions

• Osteoblasts: responsible for ossification (bone formation) by secreting organic material and inorganic salts.
• Osteoclasts: large multinucleated cells derived from monocytes; responsible for bone resorption.
• Osteocytes: mature bone cells performing routine bone tissue activities.

Hormones and bone growth & maintenance

• Endocrine hormones regulating bone formation and resorption:
  • Thyrocalcitonine (calcitonin)
  • Parathormone (PTH)
• Other factors influencing bone metabolism: calcium intake/utilization, vitamin D, growth hormone, thyroid hormone, adrenocortical hormones, and level of physical activity/stress.

Calcitonin (thyrocalcitonine)

• Also called calcitonin; the only hypocalcemic hormone.
• Source: parafollicular cells (C-cells) of the thyroid; peptide of 32 amino acids.
• Actions: suppresses osteoclast activity, stimulates bone formation, increases calcium uptake by skeletal tissues.
• Calcitoni n release is stimulated by hypercalcemia; acts to counter parathormone effects.
• Clinical notes: overproduction occurs in medullary thyroid carcinomas; high RIA levels suggest this tumor; may be associated with MEN II and goiter; even very high calcitonin does not always normalize calcium balance.
• Practical imaging note: hypercalcitoninemia can be used as a tumor marker; imaging pharmacodynamics influenced by calcitonin in bone turnover.

Parathormone (PTH)

• Structure: single polypeptide chain of 84 amino acids; the last 34 amino acids confer biological activity.
• Produced by chief cells of the parathyroid glands (typically on posterior thyroid surface).
• Main role: regulates calcium and phosphate levels in plasma.
• Actions:
  • In bone: increases resorption; favors osteoclast activity via osteoblast signaling.
  • In kidney: reabsorbs calcium; can lower serum phosphate.
• Regulation: serum calcium is the primary control of PTH secretion (hypercalcemia → suppressed; hypocalcemia → stimulated).
• Chelation therapy (e.g., EDTA) can bind calcium and stimulate PTH secretion; oversecretion leads to hypercalcemia and phosphaturia.
• Clinical scenarios:
  • Primary hyperparathyroidism: usually due to benign parathyroid adenoma or hyperplasia; aberrant location of 10% of parathyroids may complicate surgical planning; imaging agents (e.g., 201Tl, 99mTc, 99mTc-Sestamibi) used for localization.
  • Secondary hyperparathyroidism: often due to chronic renal failure or malabsorption.

Effects and pathophysiology of chronic hyperparathyroidism

• Chronic hyperparathyroidism leads to subperiosteal bone resorption, bone pain, and potential deformities; renal stones (nephrolithiasis) due to hypercalciuria; thirst and polyuria may occur.
• Diagnosis and localization are important for surgical planning; bone scans and other imaging modalities help locate overactive tissue.

Bone physiology and terminology

• Skeletal tissue includes bone and cartilage.
• Cartilage properties:
  • Avascular (lacking blood vessels, lymphatics, and nerves).
  • Flexible; collagen fibers embedded in a gel-like intercellular matrix; absorbs shock and reduces friction at joints.
• Cartilage types:
  • Hyaline cartilage: covers joint surfaces, costal cartilages, parts of the nose, larynx, trachea, bronchi; predominant in the embryonic skeleton.
  • Fibrocartilage: at the pubic symphysis, intervertebral discs; forms menisci in knees.
  • Elastic cartilage: epiglottis, external ear.
• Osteoid (bone precursor): contains osteoblasts; undergoes mineralization of collagen fibers; is a rigid, mineralized tissue. Bone is constantly remodeled.
• Periosteum: fibrous membrane around bone; site of osteoblastic activity; anchors tendons/ligaments; contains nerve fibers; growth in diameter via periosteal apposition (intramembranous ossification for most long/flat bones).
• Mineralization and remodeling:
  • Hydroxyapatite crystals deposit in collagen, providing mineral phase.
  • Bone remodeling driven by mechanical stress and activity.
• Canaliculi are small channels that allow tissue fluid to bathe crystal surfaces, enabling ion exchange.

Bone vasculature and marrow

• Blood supply to bone: nutrient arteries (shaft) delivering blood to medullary cavity; extensive capillary network ensures no cell is more than ~0.1 mm from a capillary.
  • Nutrient artery system supplies ~75% of compact bone and all medullary cavity.
  • Periosteal arteries (from surrounding muscles) can back up nutrient supply if obstruction occurs.
• Bone marrow types:
  • Red marrow (active): blood-forming stem cells; found in cranium, flat bones, vertebral bodies, proximal ends of long bones; more prolific in fetus/newborns/young children.
  • Yellow marrow (inactive): fat storage.

Imaging context and bone physiology fundamentals

• Imaging bones relies on uptake by osteoblastic activity and mineral exchange with hydroxyapatite.
• Factors influencing uptake: blood flow, bone turnover, mechanical loading, and sympathetic innervation (which influences capillary tone).
• Diffusion and binding determinants:
  • Fluorine-18 (F-18) exchange: F- substitutes for OH- in HA; low protein binding and minimal RBC binding create high-contrast images; rapid blood clearance; physical half-life ~1.8 hours; requires PET facility.
  • Tc-99m phosphate agents bind to calcium ions in HA; also bind to ACP (amorphous calcium phosphate) in active osteogenesis sites.

Radiopharmaceuticals for bone imaging

• Historically used isotopes/agents and rationale:
  • Early calcium analogs (Sr-85, Sr-87m) showed limitations due to high dose and logistical issues.
  • Tc-99m polyphosphates and pyrophosphates (PPi) allowed rapid blood clearance and bone uptake with improved imaging characteristics.
  • Diphosphonates (e.g., methylene diphosphonate, MDP) and hydroxymethyl diphosphonate (HMDP) were developed to improve bone targeting and imaging timing.
• Tc bone agents production and quality control:
  • Kits come sterile and contain lyophilized material and stannous ion (Sn2+) to reduce pertechnetate.
  • Activity limits, shelf-life, and storage restrictions apply.
  • Quality control includes ITLC (instant thin-layer chromatography) to ensure % bound and to detect hydrolyzed-reduced colloid.
  • Common issues increasing colloid impurities: excessive tin, high pH beyond 4–6, air/oxidation, and radiolysis when large activities are used.
  • Antioxidants (ascorbic acid or gentisic acid) can reduce oxidation; gentisic acid suitable with PPi to avoid kidney-accumulation issues; nitrogen purging of vials minimizes oxidation.
  • Free pertechnetate presence leads to stomach/thyroid uptake; purification steps and inert atmosphere reduce this risk.
• Biologic distribution after IV Tc agents (approximate by 3 hours):
  • Blood, urine (renal function dependent), and skeleton predominant distribution.
  • PPi: ~43% in plasma and ~30% in red cells; EHDP/MDP: protein-bound with little red cell binding.
  • Urinary excretion varies: ~43% (PPi) and ~59% (MDP/EHDP) cleared from blood by 3 hours; some 3–8% remaining in blood.
  • Normal bone uptake around 50% (±5%) of injected dose by 3 hours; HMDP shows ≈20% higher uptake than MDP.

Uptake mechanisms and why bone agents accumulate

• General uptake prerequisites:
  • Access to bone via blood supply; diffusion not blocked by protein binding or excessive molecular size/charge.
  • Fluorine (F-) exchanges with hydroxyl groups in HA; low protein binding, minimal RBC affinity, high contrast.
  • Tc phosphate agents (e.g., PPi, MDP) bind to Ca2+ in HA; some agents bind to ACP, reflecting embryonic or repair bone processes.
• Relation to disease: lesions with osteogenesis (repair or active osteoblastic activity) show increased uptake due to ACP deposition and higher remodeling.

Radiation dosimetry and safety for Tc bone agents

• Dosimetry assumptions often approximate uniform skeletal distribution; in reality, uptake is often axially focused.
• Pediatric considerations: in non-fused epiphyses (children/teens), lesion-to-diaphragm concentrations can be 2–3× higher, up to 6–8× in infants/young children.
• Critical organ: urinary bladder is typically the organ receiving the highest dose; hydration and bladder voiding reduce radiation dose.
• Toxicity concerns: hypocalcemia due to bone binding could cause tetany; minimum safety ratio between clinical dose and hypocalcemic toxicity is about 55 (i.e., used dose is <2% of minimally toxic amount).

Altered biodistribution and factors affecting uptake

• Various drugs and treatments can alter bone imaging uptake patterns (iatrogenic effects):
  • Chemotherapeutics (e.g., vincristine, doxorubicin/Adriamycin, cyclophosphamide) can increase renal parenchymal uptake.
  • Chronic steroids decrease bone mineralization and reduce uptake across the skeleton.
  • Hormonal therapies (e.g., diethylstilbestrol) can produce bilateral breast uptake in males.
  • Injections sites (iron injections), MI scars, defibrillator paddles, etc., may show localized uptake.
  • Diseases like sickle-cell anemia can show splenic uptake; aluminum overload can cause hepatic uptake.
• Attenuation factors: patient clothing, metal implants, coins, surgical hardware, and recent NM procedures can affect distribution and image appearance.
• Physiologic variances and normal variants can mimic disease: articular cartilage joints, acromio-clavicular and sternoclavicular joints, costochondral junctions, skull regions, and the anterior humeral head where muscle insertions can cause uptake.

Major uptake determinants in bone imaging

• Three principal mechanisms determine uptake in bone:
  • Bony metabolic rate
  • Local blood flow
  • Sympathetic tone (influences capillary tone and regional blood flow; loss of sympathetic innervation increases diffusion/flow in affected regions).
• Clinical examples of these mechanisms include stroke, spinal cord injuries, fractures, osteomyelitis, and tumors affecting sympathetic innervation.

The normal bone scan and pediatric considerations

• Normal bone scan symmetry: symmetric distribution and similar intensity left vs right are essential indicators of a normal scan.
• In adults, soft tissue activity should be minimal; urinary tract activity (kidneys, ureters, and bladder) may be visible.
• Delayed static images beyond 4 hours may cause soft tissue activity to disappear in normal individuals; however, renal insufficiency may prolong uptake in soft tissue.
• Normal sites of uptake on delayed views include:
  • Acromio-clavicular joints, tips of scapulae, costochondral junctions, sternum, sacroiliac joints, and frontal/parasagittal calvarium regions.
  • Cervical spine vertebrae due to lordotic curvature may appear hot.
  • Deltoid insertion at the proximal humerus can show asymmetrical uptake in ~1 in 14 individuals.
  • Linear rib uptake along posterior ribs near rib-spinal junctions may be seen in ~1 in 14 cases due to rib muscle insertions.
• Pediatric peculiarities: growth plates show intense, symmetric uptake; asymmetry may indicate osteomyelitis or neuroblastoma metastasis; ossification centers (ischiopubic joint) can complicate interpretation during fusion; cranial sutures may show uptake.

Bone scans and metastatic disease

• Typical primary sources for bone metastases: breast, lung, prostate, lymphoma, thyroid, renal, neuroblastoma.
• About 1 in 20 patients with negative bone scans will have positive X-rays; some lesions are osteolytic with little/no osteoblastic reaction.
• Laboratory tests useful for detecting bone metastases (less sensitive than bone scans): alkaline phosphatase, acid phosphatase, and PSA for prostate primaries.
• Pain correlation: about half of patients with metastases have pain; ~10% with bone metastases have no detectable metastases on bone scan.
• Distribution patterns: ~80% metastases in axial skeleton (skull 10%, vertebral column 39%, ribs/sternum 28%); appendicular skeleton commonly involves pelvis (12%) and proximal long bones (10%). Axial skeleton sites are often red bone marrow active.
• Solitary lesions: in patients with known primary tumors, solitary lesions have about a 50% likelihood of metastasis, with location-dependent variability (e.g., ribs solitary lesions are malignant in <20% of cases; cranium solitary lesions malignant ~20%, most are benign at sutures).
• Superscans (a.k.a. beautiful bone scans): extensive skeletal uptake with little/no soft tissue uptake and little renal activity; can be caused by hormone-related, metabolic, and neoplastic conditions (prostate, breast, lung, bladder, lymphoma, hyperparathyroidism, Paget’s disease, osteomalacia, fibrous dysplasia).
• Distinguishing metastasis from metabolic disease: metastases tend to spare long bones and calvarium in comparison; metabolic diseases tend to show symmetrical, diffuse uptake.
• Sensitivity vs specificity: bone scans are highly sensitive but not highly specific; correlation with history, radiographs, CT, prior NM studies, and other tests improves diagnostic accuracy.

Making bone scans more specific

• Degenerative joint disease (DJD) is common and can complicate interpretation; most patients with DJD have abnormal images, but metastases are often near DJD sites rather than within joints (mets near joints are more common than intra-articular involvement).
• Trauma and fractures: bone scans can detect fractures, osteomyelitis, and other injuries; the appearance varies with time after injury.

Trauma and fractures on bone imaging

• Fractures (Fx): bone scans become positive as repair processes begin; by 24 hours about 80% positive, 95% by 72 hours, and 98% by 1 week post-injury; lesions can remain positive for months, with 2/3 resolving within a year and 90% by 2 years; some old fractures may still be detectable.
• Child abuse (traumatic injuries): multiple fractures in various healing stages can be detected; distinguishing new from old fractures is challenging around growth plates.
• Stress fractures: Fatigue fractures (in normal bone under repetitive stress) show increased uptake along posterior cortex of tibia with long longitudinal uptake; shin splints show hot linear uptake over a portion of the posterior tibial cortex.
• Insufficiency fractures: occur in osteoporotic, osteomalacic, Paget’s, fibrous dysplasia, or post-radiotherapy bones; X-rays can be difficult to interpret.
• Legg–Calvé–Perthes disease (Legg-Perthes): avascular necrosis of the femoral head in children, typically 4–8 years old; Tc-99m SC and pinhole imaging can show early decreased uptake in the femoral capital epiphysis with increased uptake in the acetabulum; MRI/CT may be used adjunctively.

Metabolic diseases of the skeleton

• Osteoporosis: most common metabolic bone disease; characterized by decreased bone mass and thinning of trabeculae; scans can be normal; bone mineral density (BMD) assessments are helpful.
• Disuse osteoporosis: increased blood flow and osteoblastic activity with heightened bone resorption leading to diffuse uptake.
• Osteomalacia (adult rickets): vitamin D deficiency leads to demineralization and softening; dietary deficiency or limited sunlight; progressive demineralization causes bending and deformities; imaging shows generalized increased skeletal uptake.
• Primary hyperparathyroidism: hyperactive parathyroid leading to increased bone turnover; bone scans may show uptake in demineralized sites (calvaria, mandible, acromioclavicular joints, sternum, and hands); may be present with normal scans in many patients.
• Secondary hyperparathyroidism: common in chronic renal failure; often shows a superscan with focal accumulations in distal fingers and costochondral areas; vitamin D deficiency exacerbates changes.
• Avascular necrosis (AVN): focal cold defect with surrounding increased activity; SPECT improves sensitivity compared to planar imaging (85% vs 55%); Legg-Perthes and AVN patterns may resemble infection or fracture; subcapital femoral head AVN is a typical site.
• Reflex sympathetic dystrophy (RSD) / Complex regional pain syndrome: early high-flow, high-blood-pool uptake with diffuse periarticular uptake; often after trauma; skeletal uptake improves with corticosteroid therapy.
• Heterotopic ossification: post-cord injury; early soft tissue uptake on bone scans indicates sites that may mature and ossify; serial scans track maturation.
• Osteomyelitis and infectious processes: evaluated with 4-phase bone scans (flow, blood pool, 2-hour delays, 6–24-hour delays); cellulitis must be differentiated (soft-tissue uptake predominant in early phases; bone-to-soft-tissue ratio remains elevated in osteomyelitis).
• Diagnosing osteomyelitis: combined use of Ga-67, In-111 WBCs (Indium) and Tc bone agents improves accuracy; Ga-67 shows uptake in infection and fractures; In-111 labeled WBCs accumulate at infection/inflammation sites but require careful labeling to preserve cell function; marrow imaging (Tc-sulfur colloid, SC) provides complementary information about marrow involvement and potential alternative diagnoses.

Bone marrow imaging and related techniques

• Radioiron imaging (52Fe, 59Fe) binds transferrin and reflects active erythropoiesis in the marrow; used to visualize red marrow activity.
• Labeled colloids (e.g., Tc sulfur colloid, TcSC; Indium-111 chloride) localize in RES and marrow, imaging marrow distribution and extramedullary hematopoiesis.
• TcSC advantages: good marrow distribution, useful for infarcts and AVN assessment; higher activity in axial skeleton and proximal long bones in adults; younger children show broader uptake patterns.
• Indium-111 chloride: uptake in liver and spleen, somewhat less in bone marrow than TcSC; 173 and 247 keV peaks; requires medium-energy collimator.
• Gallium-67 citrate: concentrates in liver, bowel, kidney, bone marrow and spleen; used for infection/inflammation and certain tumors; imaging times commonly at 24, 48, and 72 hours; can be positive in osteomyelitis, infections, and active tumors; compared with Tc bone scans for incongruence (Ga positive, Tc negative can indicate osteomyelitis).

Palliation of bone pain with radiopharmaceuticals

• Skeletal metastases (particularly breast and prostate) cause significant pain; palliation aims to reduce pain and improve function:
  • 32P (phosphorus-32): IV administration; historical palliation with ~370 MBq; ~33% response rate, ~40% partial, ~25% no improvement; marrow depression risk due to phosphorus uptake in marrow; dose-limiting toxicity.
  • 89Sr (strontium-89): beta emitter with T½ ≈ 50.5 days; localizes to osteoblastic lesions; typical injected dose ~150 MBq; marrow dose ~1.5 Sv; ~10% become pain-free, ~60% experience pain reduction; relief starts about a month and lasts 2–3 months; hematologic monitoring is essential.
  • 186Re and 153Sm listed as other palliation agents.
• The goal is palliation, not cure or survival extension; response is variable and dependent on disease biology and extent.

Probes and issues in soft tissue uptake

• MDP can accumulate in soft tissues with calcium presence, including:
  • Necrotic or ischemic regions (myocardial infarctions, strokes).
  • Damaged skeletal muscle after trauma or rhabdomyolysis.
  • Calcifying diseases (polymyositis, scleroderma, myositis ossificans).
  • GIT uptake in necrotizing enterocolitis or ischemic bowel.
  • Hypercalcemia can cause uptake in stomach and lungs.

Practical imaging considerations and pitfalls

• Patient positioning and rotation can mimic asymmetry; scoliosis and spinal deformities complicate interpretation.
• Retained urine can project over ribs or bones; delayed views or oblique views help.
• Urine contamination, cold defects from metallic artifacts, prosthetic components, dental work, or implants can produce uptake patterns that mimic pathology.
• Breast prostheses can create asymmetries; their presence must be accounted for in interpretation.
• Joints are common sites for degenerative changes; careful history and correlation with X-rays help distinguish degenerative vs metastatic uptake.

Summary of primary imaging modalities and their roles

• Tc-99m bone imaging: most common, highly sensitive for detecting bone pathology; provides functional information about bone turnover and osteoblastic activity.
• F-18 fluoride PET: high-contrast bone imaging with rapid blood clearance; high sensitivity but requires PET/CT facilities; limited by short half-life (t1/2 ≈ 1.8 h).
• P-32, Sr-89, Re-186, Sm-153: used for palliation of painful bone metastases; provide therapeutic dose to lesions but with marrow-related toxicity risks.
• Ga-67, In-111 WBCs: complementary modalities to differentiate infection/inflammation from metastatic disease and to evaluate osteomyelitis, especially in pediatric populations or where metal implants confound Tc imaging.

Quick reference: key numerical/data points (highlights)

• Normal composition: Organic ≈ 30%; Inorganic ≈ 45%; Water ≈ 25%
• Hydroxyapatite surface area: ≈ 200 m^2/g (as per transcript)
• 3-hour bone uptake: ≈ 45–55% of injected dose in normal bone; MDP uptake about 20% higher with HMDP vs MDP
• 3-phase bone scan timing: Flow → Blood pool → 2-hour delays → 6–24-hour delays
• Pediatric uptake differences: axial (head-to-toe) uptake can be 2–3× higher in non-fused epiphyses; infants can show 6–8× higher uptake in some regions
• Axial metastasis distribution: skull 10%, vertebral column 39%, ribs/sternum 28%
• Superscan observations: little soft tissue uptake, no or minimal renal activity; widespread skeletal uptake
• Legg-Perthes AVN imaging cue: early decreased uptake in femoral capital epiphysis with acetabular uptake; TcSC hot or league correlation with delayed imaging

Connections to broader principles and real-world relevance

• Metabolic vs metastatic disease: bone scans emphasize function and turnover rather than anatomy; this explains why metastases can be detected earlier than structural changes seen on X-ray.
• Integration with other imaging modalities (X-ray, CT, MRI, PET) improves diagnostic specificity; reliance on a single modality can lead to misinterpretation.
• Understanding skeletal physiology (blood supply, marrow distribution, remodeling) helps explain where uptake occurs and why certain diseases present with characteristic patterns (e.g., Superscans, AVN, RSD).
• Ethical and practical implications: radiation exposure, especially in pediatric populations; the balance between diagnostic yield and dose; selection of appropriate radiopharmaceuticals based on disease biology and patient-specific factors.

Quick glossary of selected terms

• ACP: Amorphous Calcium Phosphate, a substrate in bone formation and a binding target for certain phosphate agents.
• DJD: Degenerative Joint Disease.
• EV: Extramedullary hematopoiesis.
• RSD: Reflex Sympathetic Dystrophy (complex regional pain syndrome).
• OA: Osteoarthritis (degenerative joint disease).
• AVN: Avascular necrosis of bone.
• SPECT: Single-photon emission computed tomography; advanced functional imaging technique.
• PET: Positron emission tomography; used with F-18 fluoride for bone imaging.

Notes for exam preparation

• Be able to describe the major and minor bone cell types and their roles in bone remodeling.
• Understand calcitonin and PTH mechanisms, including how they regulate serum calcium and interactions with osteoblasts/osteoclasts.
• Recall the primary components of bone composition and the role of hydroxyapatite in ion exchange.
• List the evolution of bone imaging radiopharmaceuticals (PPi, MDP, EHDP, MDP derivatives) and the practical considerations in Tc-99m agent production and quality control.
• Recognize typical distribution patterns for bone-seeking agents at 3 hours post-injection and what factors alter this distribution.
• Distinguish normal bone scan features from common pitfalls and normal variants, including pediatric peculiarities.
• Memorize the major patterns of metastatic disease distribution and how solitary lesions alter management.
• Understand the rationale and limitations of palliation radiopharmaceuticals and the typical response rates and safety considerations.
• Be able to differentiate osteomyelitis from cellulitis and the role of Ga-67 and In-111 WBCs in challenging cases.
• Know the key imaging signs of AVN, RSD, heterotopic ossification, and post-traumatic changes.
• Be prepared to discuss metabolic bone diseases (osteoporosis, osteomalacia, hyperparathyroidism) and how bone scans contribute to evaluation alongside BMD and laboratory tests.